TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Patients with Serious Adverse Events (SAEs), Non-serious Adverse Events (non-SAEs) and Adverse Events of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Clinically Significant Laboratory Values as per Protocol for Selected Safety Laboratory Parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Adequately performed HIV tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IV tPA administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: number of days alive
Endpoint domain: Mortality/survival
Primary endpoint: number of days in the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: number of days with oxygen therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: average change in anal resting pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum squeeze pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average intra-balloon pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in voiding function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference of ANGPTL4 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of tumors detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Symptoms of disruptive behavior disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Smell sensation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coughing force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Primary toxicity endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Statin adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour systolic BP (SBP) lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline PSP at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change from Baseline PSP at 24 weeks
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Proportion of patients remaining in MR3.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficiency of the telephone consultation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of hepatitis B infections in infants at 1 year of age
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence of Pressure Ulcer
Endpoint domain: Mortality/survival
Primary endpoint: Time to Recurrence of Pressure Ulcer
Endpoint domain: Mortality/survival
Primary endpoint: Change in Potassium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients with MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mucociliary Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: DTPA absorption rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Health Questionnaire (PHQ-9) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychiatric Symptoms Recovery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recovery From Mental Illness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: student illness rates
Endpoint domain: Adverse events/effects
Primary endpoint: student absence rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change of Clinical Activity Score (CAS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of NOSPECS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life improvement (ICIQ-UI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life improvement (FSFI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life improvement (PISQ-12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Seroprevalence of SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: RDV Plasma CMax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RDV AUC0-∞
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RDV AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of mirabegron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catatonia on the Bush-Francis Scale (BFCRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Titers of chemokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Accepted NRT Patches
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Who Reported Household Use of NRT
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of HPV 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Function and knee score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained renal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: No of patients died within 30 days postoperatively
Endpoint domain: Mortality/survival
Primary endpoint: No of patients died within 180 days postoperatively
Endpoint domain: Mortality/survival
Primary endpoint: No of patients with major postoperative complications within 30 days after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Medical Research Council Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Transferrin Saturation (TSAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients achieving a preliminary efficacy (response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Change in Inflammatory Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With HIV-1 RNA Load <50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Death from Esophageal Squamous Cell Carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Trismus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in General patients' satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Medication Side Effects Score
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of admission to hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: percent of cornea perforation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Neuropsychiatric Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Cornell's Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in UPDRS subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Endometrial cells gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in I-PSS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new onset atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: recurrence of cardiac arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of patients' experience of meaningful learning
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: C peptide secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pulmonary and cerebral thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Clinical and laboratory safety assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical and laboratory safety and tolerability profiles
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacodynamic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Orthostatic Hypotension Symptom Assessment (OHSA) Question #1 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemophilia Joint Health Score (HJHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Musculoskeletal ultrasound/HEAD-US scoring system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: X-rays/Pettersson score (PS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of participants achieving complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with disease progression or death per patient-year
Endpoint domain: Mortality/survival
Primary endpoint: Change in Paffenbarger Physical Activity and Exercise Index scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Difference in pre and post-test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Selective attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Visual-spatial perception
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Wound evaluation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Days Until First On-study Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in predose morning FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Circadian variability of platelet inhibition assessed with VASP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Circadian variability of platelet inhibition assessed with Multiplate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient function as measured on Oswestry Disability Index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disc height maintenance as measured from standing x-rays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically symptomatic recurrent herniation at the index level, confirmed by imaging
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of MSC-specific Adverse or Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Brain Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative Oral Morphine Milligram Equivalent (OME) Consumption at 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT ratio of liver/spleen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Mass Index Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of bladder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for Alogliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alogliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alogliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Pain Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Catastrophizing Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Hemoglobin A1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in tracing smoothness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fibromyalgia Impact Questionnaire (FIQ) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mental Health Continuum-Short Form (MHC-SF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hedonic Well-Being SubScale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Eudaimonic Well-Being SubScale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IgG responses to EN41-FPA2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IgA responses to EN41-FPA2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in sex hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in cycle regularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in ovarian function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Composite of death or catheter related large vein thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: Adverse Events and side effects to the vaccines
Endpoint domain: Adverse events/effects
Primary endpoint: Change in regional brain volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Disparity Vergence Response Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of the knee Osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migration index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Rating Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with at least 50% seizure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Unexpected hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Participants With an Abnormal Condition by Anatomical Site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects in Irritation Score Category for Buccal Mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton 17 item scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and systemic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: SENSIMED Triggerfish output values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Goldmann applanation tonometry values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in Oxford Knee Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Feasibility of cognitive assessment battery administration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction Recession Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of physician visits related to surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Immune cell infiltration in minor salivary glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Late gadolinium enhancement (LGE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: True detection rate of carcinoma and adenoma lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Increase in hydrogen concentration in the breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: cerebral nimodipine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cerebral ethanol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in the Total Score of the TWSTRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrocardiogram (ECG) intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cytokine and inflammatory responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve (AUC[0-t]) for DTG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC From Time Zero to Infinity (AUC[0-inf]) for DTG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) for DTG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Very Heavy Drinking Days Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allogeneic Cell Therapy-related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Duration of Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the severity of pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ctDNA copies per milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with 4-fold or greater rises in serum vibriocidal antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Analgesics consumption postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in size of uterine fibroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: objective body composition index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waistline and Waist to hip ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of proven EBV disease
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of probable EBV disease
Endpoint domain: Adverse events/effects
Primary endpoint: Molecular and biochemical profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in delta serum 25-hydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alcohol Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core body temperature cooling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interfascial Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects developing neurological symptoms after a tick bite
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects developing other serious, non-neurological symptoms or disease after a tick bite
Endpoint domain: Adverse events/effects
Primary endpoint: Physical activity measurement accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of acyclovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Fitness Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal Fat percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Left ventricle end diastolic dimension (LVEDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood BNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high-quality embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in challenge threshold (mg food protein tolerated by oral intake)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of adolescents who received needed vaccines or well-care visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Independent Living Skills Survey (ILSS) Change
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances